Share

'We are in it for the long run,' says Odyssey Acquisition on BenevolentAI merger

Jean Raby, co-CEO of Odyssey Acquisition, discusses the company's merger with BenevolentAI, the clinical stage AI drug discovery company.
02:30
Tue, Dec 7 202111:10 AM EST